Local Inflammation in Arrhythmogenic Right Ventricular Cardiomyopathy
Overview
- Phase
- Not Applicable
- Intervention
- Peripheral immunological assessment on venous blood
- Conditions
- Arrhythmogenic Right Ventricular Dysplasia
- Sponsor
- University Hospital, Toulouse
- Enrollment
- 80
- Locations
- 1
- Primary Endpoint
- Identify the inflammatory components by interleukine1
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
The understanding of ARVC pathophysiology remains incomplete. Several clues indicate that disease progression is mediated through inflammation. The present study aim to document the feasibility of detecting the potential presence of intracardiac local inflammatory components in patients with ARVC.
Detailed Description
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a heritable condition characterized by right ventricular (RV) dilatation/dysfunction and malignant ventricular arrhythmias. The understanding of ARVC pathophysiology remains incomplete. Several clues indicate that disease progression is mediated through inflammation. First, presence of subepicardial late gadolinium enhancement sharing the same characteristics as the ones found in myocarditis is common on cardiac magnetic resonance imaging (CMR). Second, clinical pathology findings of inflammatory infiltrates of mononuclear cells are frequent and correlate to the extent and severity of ARVC. Finally, from a biological standpoint, the exploratory study conducted by Campian et al. has shown an exaggerated humoral inflammatory response in peripheral blood whilst anti-desmoglein-2 antibodies (targeting a component of the desmosome) emerge as a sensitive and specific biomarker for ARVC. As specific treatments for ARVC are currently lacking, a better understanding of the humoral pathophysiology of the disease could unlock new therapeutic targets. We recently demonstrated that collecting local cardiomyocytes was feasible through irrigated ablation catheters in patients with ARVC. These steerable catheters may easily map the whole right ventricle and locate endocardial or epicardial scars. Aspiration of local blood or cellular material through the inner lumen of the catheter once pressed on the parietal wall may be an interesting technique for retrieving local inflammation markers.
Investigators
Eligibility Criteria
Inclusion Criteria
- •For cases:
- •Arrhythmogenic right ventricular dysplasia diagnosed (according to 2010 Task Force Criteria)
- •Admitted for right ventricle electrophysiologic mapping
- •For controls \* Admitted for ablation procedures (accessory pathway, atrial flutter) on otherwise healthy hearts.
Exclusion Criteria
- •Diagnostic of systemic chronic inflammatory disease
- •Presence of possible or proven cardiac involvement of an inflammatory disease, an acute or chronic infectious disease.
- •Taking immunosuppressant or immunomodulating medications
Arms & Interventions
Patients
Carrier of a definite diagnosis of arrhythmogenic dysplasia of the right ventricle in line with the criteria of the Task Force 2010 (see Appendices), admitted for an electrical mapping of the right ventricle
Intervention: Peripheral immunological assessment on venous blood
Patients
Carrier of a definite diagnosis of arrhythmogenic dysplasia of the right ventricle in line with the criteria of the Task Force 2010 (see Appendices), admitted for an electrical mapping of the right ventricle
Intervention: Immunological assessment carried out on intracardiac material
Control case
Without heart disease, admitted for a Kent bundle ablation or endocavity procedure / Wolff-Parkinson-White syndrome or common flutter (in subjects in whom the same irrigated material will be used and for whom echocardiography will have excluded associated heart disease).
Intervention: Peripheral immunological assessment on venous blood
Control case
Without heart disease, admitted for a Kent bundle ablation or endocavity procedure / Wolff-Parkinson-White syndrome or common flutter (in subjects in whom the same irrigated material will be used and for whom echocardiography will have excluded associated heart disease).
Intervention: Immunological assessment carried out on intracardiac material
Outcomes
Primary Outcomes
Identify the inflammatory components by interleukine1
Time Frame: 24 months
Rate of interleukin 1 beta in the blood
Identify the inflammatory components by C-reactive protein
Time Frame: 24 months
Rate of C-reactive protein in the blood
Identify the inflammatory components by interleukine10
Time Frame: 24 months
Rate of interleukin 10 in the blood
Identify the inflammatory components by Transforming Growth Factor
Time Frame: 24 months
Rate of Transforming Growth Factor beta in the blood
Identify the inflammatory components by onterleukine6
Time Frame: 24 months
Rate of interleukin 6 in the blood
Identify the inflammatory components by Tumor Necrosis Factor
Time Frame: 24 months
Rate of Tumor Necrosis Factor alpha in the blood